Evidence–practice gaps in chronic kidney disease management among patients taking antidiabetic or antihypertensive medications: a nationwide analysis of Japanese primary care electronic health records
Open Access
- 3 April 2026
- journal article
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 30 (6) , 856-865
Abstract
Background: The management of chronic kidney disease (CKD) in primary care remains poorly defined despite primary care physicians managing a high proportion of patients with hypertension and diabetes. This study examined CKD-related laboratory testing and anemia management patterns in Japanese primary care settings. Methods: Using the Japan Medical Data Survey (JAMDAS) database, we analyzed electronic health records from Japanese primary care clinics. We included patients aged ≥ 18 years who received antihypertensive or antidiabetic medications at least twice in 2024 and visited clinics quarterly, excluding those who received kidney replacement therapy. Results: Among 859,044 eligible patients (mean age: 70.3 years; men: 48.9%), estimated glomerular filtration rate, dipstick proteinuria, serum potassium, and hemoglobin were measured in 76.2%, 11.2%, 62.9%, and 69.6% of patients, respectively. Proteinuria testing declined with increasing age. Of 604,936 patients who underwent any anemia-related laboratory testing, only 5.1%, 0.4%, and 15.1% had their serum ferritin, transferrin saturation, and serum iron measured, respectively. Among 5219 patients with coded renal anemia, 73.9% received erythropoiesis-stimulating agents (ESAs) or hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Notably, 58.6% of 553 patients with a renal anemia diagnosis and hemoglobin levels ≥ 13 g/dL were treated with ESAs or HIF-PHIs. Conclusion: Evidence–practice gaps in CKD management were identified in Japanese primary care settings, including limited proteinuria testing and raising hemoglobin levels above guideline-recommended limits, despite inadequate evaluation of iron parameters. These findings indicate that systematic quality improvement initiatives are needed to improve CKD management in primary care.Keywords
Funding Information
- Kyowa Kirin
This publication has 32 references indexed in Scilit:
- Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitorsClinical and Experimental Nephrology, 2025
- The diagnostic status of chronic kidney disease in a real-world database in Japan: CHECK-CKDClinical and Experimental Nephrology, 2025
- First-time diagnosis and referral practices for individuals with CKD by primary care physicians: a study of electronic medical records across multiple clinics in JapanClinical and Experimental Nephrology, 2025
- Factors associated with awareness of chronic kidney disease, and impact of awareness on renal prognosisClinical and Experimental Nephrology, 2024
- The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemiaClinical and Experimental Nephrology, 2024
- Trace proteinuria detected via dipstick test is associated with kidney function decline and new-onset overt proteinuria: the Japan Specific Health Checkups (J-SHC) StudyClinical and Experimental Nephrology, 2023
- A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future PerspectivesAdvances in Therapy, 2021
- Underestimating chronic kidney disease by urine dipstick without serum creatinine as a screening tool in the general Japanese populationClinical and Experimental Nephrology, 2014
- Budget impact analysis of chronic kidney disease mass screening test in JapanClinical and Experimental Nephrology, 2014
- Cost-effectiveness of chronic kidney disease mass screening test in JapanClinical and Experimental Nephrology, 2011